Zeria Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the Year Ending March 31, 2023. For the year, the company expects net sales of JPY 66,000 million, operating profit of JPY 7,000 million, profit attributable to owners of parent JPY 5,600 million and basic earnings per share of JPY 126.73.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,001 JPY | -5.12% | -5.57% | -0.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.79% | 566M | |
+19.62% | 43.27B | |
+24.52% | 22.92B | |
+20.29% | 15.43B | |
+7.48% | 12.95B | |
+42.51% | 11.83B | |
-8.84% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.13% | 5.55B |
- Stock Market
- Equities
- 4559 Stock
- News Zeria Pharmaceutical Co., Ltd.
- Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023